These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 35599187)

  • 1. The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
    Loriot Y; Texier M; Culine S; Fléchon A; Thiery-Vuillemin A; Gravis G; Geoffrois L; Chevreau C; Gross-Goupil M; Barthelemy P; Bompas E; Mahammedi H; Laguerre B; Lacourtoisie SA; Helissey C; Ladoire S; Abraham C; Massard C; Grimaldi S; Fizazi K
    Eur Urol; 2022 Aug; 82(2):172-179. PubMed ID: 35599187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Role of Early Interim Fluorodeoxyglucose Positron Emission Tomography in Patients With Advanced Seminoma Undergoing Standard Treatment.
    Raggi D; Bandini M; Giannatempo P; Farè E; Marandino L; Colecchia M; Calareso G; Padovano B; Serafini G; Alessi A; Necchi A
    Clin Genitourin Cancer; 2021 Jun; 19(3):237-245.e2. PubMed ID: 32980271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interim (18)F-Fluorodeoxyglucose Positron Emission Tomography for Early Metabolic Assessment of Response to Cisplatin, Etoposide, and Bleomycin Chemotherapy for Metastatic Seminoma: Clinical Value and Future Directions.
    Necchi A; Nicolai N; Alessi A; Miceli R; Giannatempo P; Raggi D; Tana S; Serafini G; Padovano B; Mariani L; Crippa F; Salvioni R
    Clin Genitourin Cancer; 2016 Jun; 14(3):249-54. PubMed ID: 26433626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET.
    Bokemeyer C; Kollmannsberger C; Oechsle K; Dohmen BM; Pfannenberg A; Claussen CD; Bares R; Kanz L
    Br J Cancer; 2002 Feb; 86(4):506-11. PubMed ID: 11870528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. False-positive fluorodeoxyglucose positron emission tomography results after chemotherapy in patients with metastatic seminoma.
    Decoene J; Winter C; Albers P
    Urol Oncol; 2015 Jan; 33(1):23.e15-23.e21. PubMed ID: 25454484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can we rely on PET in the follow-up of advanced seminoma patients?
    Siekiera J; Małkowski B; Jóźwicki W; Jasiński M; Wronczewski A; Pietrzak T; Chmielowska E; Petrus A; Kamecki K; Mikołajczak W; Kraśnicki K; Chłosta P; Drewa T
    Urol Int; 2012; 88(4):405-9. PubMed ID: 22507953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two decades of FDG-PET/CT in seminoma: exploring its role in diagnosis, surveillance and follow-up.
    Conduit C; Koh TT; Hofman MS; Toner GC; Goad J; Lawrentschuk N; Tai KH; Lewin JH; Tran B
    Cancer Imaging; 2022 Oct; 22(1):58. PubMed ID: 36209121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiotherapy for Post-Chemotherapy Residual Mass in Advanced Seminoma: A Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography-Based Risk-adapted Approach.
    Murthy V; Karmakar S; Carlton J; Joshi A; Krishnatry R; Prabhash K; Noronha V; Bakshi G; Prakash G; Pal M; Menon S; Agrawal A; Rangarajan V
    Clin Oncol (R Coll Radiol); 2021 Jul; 33(7):e315-e321. PubMed ID: 33608206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker].
    Pfannenberg AC; Oechsle K; Kollmannsberger C; Dohmen BM; Bokemeyer C; Bares R; Vontheim R; Claussen CD
    Rofo; 2004 Jan; 176(1):76-84. PubMed ID: 14712410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of carboplatin AUC-10 guided by positron emission tomography-defined metabolic response in metastatic seminoma.
    Shamash J; Syed R; Sarker SJ; Sarwar N; Sharma A; Mutsvangwa K; Coetzee C; Wilson P; Rustin GJ
    Eur J Cancer; 2019 Jul; 115():128-135. PubMed ID: 31136925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study.
    Fizazi K; Delva R; Caty A; Chevreau C; Kerbrat P; Rolland F; Priou F; Geoffrois L; Rixe O; Beuzeboc P; Malhaire JP; Culine S; Aubelle MS; Laplanche A
    Eur Urol; 2014 Feb; 65(2):381-6. PubMed ID: 24094847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of 18F-FDG PET/CT in Characterization of Equivocal Lesions in High-Risk Testicular Carcinoma in Restaging Setting.
    Rasheed R; Al-Kandari F; Ghanem M; Marafi F; Usmani S
    Asian Pac J Cancer Prev; 2020 Feb; 21(2):511-515. PubMed ID: 32102532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in the postchemotherapy management of patients with seminoma: systematic review and meta-analysis.
    Treglia G; Sadeghi R; Annunziata S; Caldarella C; Bertagna F; Giovanella L
    Biomed Res Int; 2014; 2014():852681. PubMed ID: 24963486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.
    Minamimoto R; Fayad L; Advani R; Vose J; Macapinlac H; Meza J; Hankins J; Mottaghy F; Juweid M; Quon A
    Radiology; 2016 Jul; 280(1):220-9. PubMed ID: 26854705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET imaging in testicular tumours.
    Calabrò D; Telo S; Ambrosini V
    Curr Opin Urol; 2020 Sep; 30(5):665-671. PubMed ID: 32732623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Assessment of residual tumours after systemic treatment of metastatic seminoma: ¹⁸F-2-fluoro-2-deoxy-D-glucose positron emission tomography - meta-analysis of diagnostic value].
    Müller J; Schrader AJ; Jentzmik F; Schrader M
    Urologe A; 2011 Mar; 50(3):322-7. PubMed ID: 21161157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial.
    Bryan LJ; Casulo C; Allen PB; Smith SE; Savas H; Dillehay GL; Karmali R; Pro B; Kane KL; Bazzi LA; Chmiel JS; Palmer BA; Mehta J; Gordon LI; Winter JN
    JAMA Oncol; 2023 May; 9(5):683-691. PubMed ID: 36928527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial.
    De Santis M; Becherer A; Bokemeyer C; Stoiber F; Oechsle K; Sellner F; Lang A; Kletter K; Dohmen BM; Dittrich C; Pont J
    J Clin Oncol; 2004 Mar; 22(6):1034-9. PubMed ID: 15020605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG PET for detection and therapy control of metastatic germ cell tumor.
    Cremerius U; Effert PJ; Adam G; Sabri O; Zimmy M; Wagenknecht G; Jakse G; Buell U
    J Nucl Med; 1998 May; 39(5):815-22. PubMed ID: 9591582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular Tumour Working Party.
    Horwich A; Oliver RT; Wilkinson PM; Mead GM; Harland SJ; Cullen MH; Roberts JT; Fossa SD; Dearnaley DP; Lallemand E; Stenning SP;
    Br J Cancer; 2000 Dec; 83(12):1623-9. PubMed ID: 11104556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.